SpringWorks Therapeutics Announces Data to Be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) today announced that four abstracts from the company's portfolio will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31 to June 4, 2024.
Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The consensus estimated revenue n
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
STAMFORD, Conn., May 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announ
Express News | HC Wainwright & Co. Reiterates Buy on SpringWorks Therapeutics, Maintains $74 Price Target
SpringWorks Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 64.04% HC Wainwright & Co. → $74 Reiterates Buy → Buy 03/06/2024 66.26% JP Morgan $74 → $75 Mai
Analysts Conflicted on These Healthcare Names: Springworks Therapeutics (SWTX) and Becton Dickinson (BDX)
Earnings Call Summary | SpringWorks Therapeutics(SWTX.US) Q1 2024 Earnings Conference
The following is a summary of the SpringWorks Therapeutics, Inc. (SWTX) Q1 2024 Earnings Call Transcript:Financial Performance:SpringWorks Therapeutics reported revenue of $21 million after the succes
Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
Express News | SpringWorks Therapeutics Inc : Wedbush Raises Target Price to $75 From $70
Wedbush Raises SpringWorks Therapeutics' Price Target to $75 From $70, Keeps Outperform Rating
SpringWorks Therapeutics (SWTX) has an average rating of buy and price targets ranging from $58 to $80, according to analysts polled by Capital IQ. Price: 43.54, Change: -3.30, Percent Change: -7.05
Express News | SpringWorks Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 EPS Results
Express News | SpringWorks Therapeutics Shares Reverse Premarket Gains, Last Down 6.7%
Buy Rating for Springworks Therapeutics Amid Strong Market Performance and Promising Pipeline
Express News | SpringWorks Therapeutics Shares up 6.7% Premarket After Q1 Results
Express News | Springworks' Cash, Cash Equivalents And Marketable Securities Were $573M As Of March 31, 2024
Express News | SpringWorks Therapeutics : Cash, Cash Equivalents, & Marketable Securities: Cash, Cash Equivalents &Marketable Securities Were $573.0 Mln as of Mar 31
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q1 Revenue $21M, Vs. Street Est of $13.1M
06:31 AM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q1 Revenue $21M, vs. Street Est of $13.1M
Express News | SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
Express News | SpringWorks Therapeutics Q1 Basic EPS USD -1.18
Springworks Therapeutics (SWTX) Receives a Buy From Barclays